易瑞生物(300942) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥146,917,926.77, representing a 103.46% increase compared to ¥72,209,692.72 in the same period last year[7] - Net profit attributable to shareholders for Q1 2021 was ¥87,610,355.16, a 150.10% increase from ¥35,030,572.53 year-on-year[7] - The net profit after deducting non-recurring gains and losses was ¥79,440,063.33, up 133.33% from ¥34,045,540.77 in the previous year[7] - The basic earnings per share for Q1 2021 was ¥0.23, reflecting a 155.56% increase from ¥0.09 in the same quarter last year[7] - The company reported a net profit of CNY 89,853,820.63 for the quarter, reflecting strong operational performance[47] - The net profit for Q1 2021 reached CNY 87,599,429.10, up from CNY 35,021,960.21 in the same period last year, representing a growth of approximately 150%[48] - The total comprehensive income for Q1 2021 was CNY 86,965,485.64, compared to CNY 35,300,634.11 in the prior year, showing a growth of about 146%[49] Assets and Liabilities - The total assets at the end of the reporting period were ¥998,848,324.21, a 52.99% increase from ¥652,886,483.47 at the end of the previous year[7] - The total assets of the company reached CNY 998.85 million, up from CNY 652.89 million at the end of 2020, indicating a growth of 52.8%[39] - Total liabilities rose to CNY 176,648,028.56, compared to CNY 103,348,477.74 in the previous period[44] - Total current liabilities stand at CNY 77,564,602.37, showing a stable short-term financial position[67] Cash Flow - The net cash flow from operating activities was ¥98,176,735.85, a significant recovery from a negative cash flow of -¥20,689,163.91 in the same period last year[7] - Cash flow from operating activities was CNY 168,141,233.13, significantly higher than CNY 68,922,745.94 in the same period last year, demonstrating improved cash generation[55] - The net cash flow from financing activities was ¥182,706,115.09, a substantial increase from ¥21,997,320.65 in the previous year, highlighting successful fundraising efforts[57] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,501[10] - The largest shareholder, Shenzhen Yirui Holdings Co., Ltd., held 37.67% of the shares, amounting to 151,001,310 shares[10] Research and Development - R&D investment totaled 10.69 million yuan, up 27.73% from the same period last year, accounting for 7.28% of total revenue[19] - Research and development expenses for Q1 2021 amounted to CNY 10,690,252.58, compared to CNY 8,247,570.76 in the previous year, indicating an increase in investment in innovation[51] Government Subsidies and Other Income - The company received government subsidies amounting to ¥9,595,211.92 during the reporting period[8] - The company achieved a 210.57% increase in other income, totaling ¥3,595,211.92, primarily due to increased government subsidies[18] Inventory and Accounts Receivable - The company reported a significant increase in accounts receivable, rising by 745.11% to ¥2,693,583.00 due to an increase in bank acceptance bills received[17] - Inventory increased by 42.94% to ¥88,038,529.64, reflecting the company's growth in revenue and stock preparation[17] Market Presence and Future Plans - The company plans to expand its production capacity, leading to an increase in non-current assets by 98.97% to ¥13,550,104.77[17] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[47] Compliance and Governance - The company has undergone a board and supervisory committee restructuring, with new members elected in March 2021[26] - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[33]